Asenapine in Bipolar Disorder

McIntyre, Roger S.

doi:10.1002/9780470975114.ch13

Cited by 1 publication

(1 citation statement)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…18,19 There is also a 12-week, controlled trial comparing asenapine with placebo as an adjunctive therapy added to either lithium or valproate in bipolar I adults (n = 324) experiencing an acute manic or mixed episode. At 52 weeks, clinically significant weight gain was higher in the olanzapine (55%) vs. the asenapine (36%) group, with a 9% increase in the rate of metabolic syndrome on olanzapine vs. a 3% decrease on asenapine.…”

Section: Clinical Trials In Bipolar Disordermentioning

confidence: 99%

Asenapine

Janicak

Rado

2009

Psychopharm Review

View full text Add to dashboard Cite

T his issue reviews the clinical trial data for asenapine, one of the two recently approved antipsychotics in the United States. A subsequent issue will report on iloperidone. Asenapine is the latest agent to receive FDA approval for both the acute treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder in adults. It is marketed in the United States under the trade name Saphris (Schering Corp.) and is administered sublingually (SL). The recommended starting and target dose for schizophrenia is 5 mg twice daily, and the recommended starting dose for bipolar I disorder is 10 mg twice daily. The safety of asenapine at doses greater than 10 mg SL BID has not been assessed in clinical trials. This review will consider asenapine's neuroreceptor profile, the data to support its utility in managing various symptoms associated with these disorders, and how asenapine may distinguish itself from other agents in its class.

show abstract

Section: Clinical Trials In Bipolar Disordermentioning

confidence: 99%